Ariclaim

RSS

duloxetine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Ariclaim has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 07/08/2018

Authorisation details

Product details
Name
Ariclaim
Agency product number
EMEA/H/C/000552
Active substance
duloxetine
International non-proprietary name (INN) or common name
duloxetine
Therapeutic area (MeSH)
Diabetic Neuropathies
Anatomical therapeutic chemical (ATC) code
N06AX21
Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
26
Date of issue of marketing authorisation valid throughout the European Union
11/08/2004
Contact address

Papendorpseweg 83
3528 BJ Utrecht
Netherlands

Product information

09/12/2016 Ariclaim - EMEA/H/C/000552 - N/0066

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

Treatment of diabetic peripheral neuropathic pain.

Ariclaim is indicated in adults.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating